Related Experiment Videos
Retinoic acid syndrome
Debapriya Datta1, Daniel A Gerardi
1Dept of Pulmonary and Critical Care Medicine, St Francis Hospital and Medical Center, 114, Woodland Street, Hartford, CT 06105, USA.
Connecticut Medicine
|November 19, 2003
Summary
All-transretinoic acid (ATRA) treats acute promyelocytic leukemia (APL) but can cause Retinoic Acid Syndrome (RAS). Prompt recognition and treatment of RAS are crucial for patient outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- All-transretinoic acid (ATRA) is a Vitamin A derivative used to treat acute promyelocytic leukemia (APL).
- Retinoic Acid Syndrome (RAS) is a known complication during ATRA treatment for APL.
- RAS presents as a constellation of clinical signs and symptoms.
Observation:
- Diagnosis of RAS in APL patients treated with ATRA requires at least three features: fever, dyspnea, weight gain, hypotension, renal failure, pulmonary infiltrates, pleural effusion, or pericardial effusion.
- Pulmonary manifestations, particularly pulmonary edema, are the most frequent clinical presentation of RAS.
- The incidence of RAS ranges from 6% to 27% among APL patients treated with ATRA.
Findings:
- The exact pathogenesis of Retinoic Acid Syndrome remains incompletely understood.
- RAS can be a life-threatening condition if not identified and managed promptly.
- This report details a case of RAS in a young male patient with APL undergoing ATRA therapy.
Implications:
- Early identification and management of RAS are critical for improving patient survival in APL.
- Understanding RAS pathogenesis may lead to improved treatment strategies and preventative measures.
- This case highlights the importance of vigilance for RAS in patients receiving ATRA for APL.